Skip to content

Webinar: "Reverse Payments" from Actavis to California AB 824: The Current State of Litigation Settlements in the Hatch-Waxman/BCPIA Space

Since the Supreme Court’s seminal decision in Actavis, brand and generic drug companies have been working within the antitrust framework laid out in that decision to craft patent litigation settlements.

But California’s new law creating more stringent antitrust scrutiny for Hatch-Waxman and BPCIA settlements, AB 824, threw a curveball in strategies that had been well-established.

Join A&O members of the antitrust and patent settlement team for a discussion on recent issues impacting pharmaceutical patent litigation settlements, such as license dates with acceleration provisions, litigation avoidance fees, and strategies for mitigating the antitrust risk in each of these and other relevant areas.

Date and time of webinar

June 22, 2022

12:00pm - 1:00pm EST